cyclophosphamide + fludarabine phosphate

This entry refers to a specific non-myeloablative conditioning regimen evaluated in a Phase II clinical trial conducted by the Roswell Park Cancer Institute. The protocol utilizes a combination of the alkylating agent **cyclophosphamide** and the purine antimetabolite **fludarabine phosphate** to prepare patients for allogeneic hematopoietic stem cell transplantation. This regimen is designed to provide sufficient immunosuppression to allow for donor cell engraftment and the subsequent induction of a graft-versus-tumor effect, while minimizing the severe systemic toxicities typically associated with traditional myeloablative conditioning. It is primarily investigated for use in patients with various hematologic malignancies (such as leukemia and lymphoma) or aplastic anemia who are ineligible for intensive transplant protocols due to age or comorbidities.

Other names

cyclophosphamide-Roswell Park Cancer Institute-hematologic malignancy-aplastic anemiaFlu/Cy conditioningNon-myeloablative conditioning with cyclophosphamide and fludarabine